These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8787101)

  • 1. [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].
    Trouillas P; Xie J; Getenet JC; Adeleine P; Nighoghossian N; Honnorat J; Riche G; Derex L
    Rev Neurol (Paris); 1995 Dec; 151(12):708-13. PubMed ID: 8787101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia.
    Trouillas P; Xie J; Adeleine P
    Prog Brain Res; 1997; 114():589-99. PubMed ID: 9193169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
    Trouillas P; Xie J; Adeleine P; Michel D; Vighetto A; Honnorat J; Dumas R; Nighoghossian N; Laurent B
    Arch Neurol; 1997 Jun; 54(6):749-52. PubMed ID: 9193210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Buspirone in the treatment of cerebellar ataxia].
    Svetel M; Vojvodić N; Filipović SR; Dragasević N; Sternić N; Kostić VS
    Srp Arh Celok Lek; 1999; 127(9-10):312-5. PubMed ID: 10649900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of buspirone for the treatment of cerebellar ataxia in an older individual.
    Holroyd-Leduc JM; Liu BA; Maki BE; Zecevic A; Herrmann N; Black SE
    Can J Clin Pharmacol; 2005; 12(3):e218-21. PubMed ID: 16278493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Buspirone chlorhydrate in the treatment of cerebellar ataxia].
    Andrade-Filho AS; Passos-Almeida J; Andrade-Souza VM; Sena-Pereira LR
    Rev Neurol; 2002 Aug 16-31; 35(4):301-5. PubMed ID: 12235556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
    Trouillas P; Garde A; Robert JM; Adeleine P
    C R Seances Acad Sci III; 1981 Jan; 292(1):119-22. PubMed ID: 6786764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy.
    Heo JH; Lee ST; Chu K; Kim M
    J Neurol Sci; 2008 Aug; 271(1-2):87-90. PubMed ID: 18466925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cerebellar ataxia with 5-HT1A agonist.
    Takei A; Hamada T; Yabe I; Sasaki H
    Cerebellum; 2005; 4(3):211-5. PubMed ID: 16147954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of buspirone for treatment of cerebellar ataxia. An open-label study.
    Lou JS; Goldfarb L; McShane L; Gatev P; Hallett M
    Arch Neurol; 1995 Oct; 52(10):982-8. PubMed ID: 7575226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study.
    Lee ST; Park JH; Kim M
    Headache; 2005 Sep; 45(8):1004-11. PubMed ID: 16109114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cerebellar ataxia with buspirone: a double-blind study.
    Trouillas P; Xie J; Adeleine P
    Lancet; 1996 Sep; 348(9029):759. PubMed ID: 8806320
    [No Abstract]   [Full Text] [Related]  

  • 14. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
    Trouillas P; Garde A; Robert JM; Renaud B; Adeleine P; Bard J; Brudon F
    Rev Neurol (Paris); 1982; 138(5):415-35. PubMed ID: 6983101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying the 5-HT1A agonist action of buspirone in man.
    Bridge MW; Marvin G; Thompson CE; Sharma A; Jones DA; Kendall MJ
    Psychopharmacology (Berl); 2001 Nov; 158(3):224-9. PubMed ID: 11713611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases.
    Wessel K; Hermsdörfer J; Deger K; Herzog T; Huss GP; Kömpf D; Mai N; Schimrigk K; Wittkämper A; Ziegler W
    Arch Neurol; 1995 May; 52(5):451-5. PubMed ID: 7733838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design.
    Megna J; O'dell M
    Arch Phys Med Rehabil; 2001 Aug; 82(8):1145-8. PubMed ID: 11494197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validating an Ataxia Functional Composite Scale in spinocerebellar ataxia.
    Assadi M; Leone P; Veloski JJ; Schwartzman RJ; Janson CG; Campellone JV
    J Neurol Sci; 2008 May; 268(1-2):136-9. PubMed ID: 18191149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic buspirone treatment normalizes open field behavior in olfactory bulbectomized rats: assessment with a quantitative autoradiographic evaluation of the 5-HT1A binding sites.
    Sato H; Skelin I; Debonnel G; Diksic M
    Brain Res Bull; 2008 Mar; 75(5):545-55. PubMed ID: 18355630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of the Scale for Assessment and Rating of Ataxia (SARA).
    Yabe I; Matsushima M; Soma H; Basri R; Sasaki H
    J Neurol Sci; 2008 Mar; 266(1-2):164-6. PubMed ID: 17950753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.